99 related articles for article (PubMed ID: 26262682)
1. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.
Okuma Y; Shintani Y; Sekine I; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Yamamoto N; Kawaguchi T; Miyaoka E; Yoshino I; Date H
Clin Lung Cancer; 2024 Jun; 25(4):336-346.e2. PubMed ID: 38360497
[TBL] [Abstract][Full Text] [Related]
3. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations.
Xiong K; Yang Y; Yang Y; Wang Z; Liu Y; Duo H; Yuan X; Xiao Y; Xiao H; Yang X
Neoplasia; 2024 Jul; 53():101006. PubMed ID: 38761505
[TBL] [Abstract][Full Text] [Related]
4. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer.
Itaya T; Yamaoto N; Ando M; Ebisawa M; Nakamura Y; Murakami H; Asai G; Endo M; Takahashi T
Cancer Sci; 2007 Feb; 98(2):226-30. PubMed ID: 17233840
[TBL] [Abstract][Full Text] [Related]
5. Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma.
Qiao X; Zhang Y; Wang J; Nong J; Li X; Yang X; Lv J; Zhang H; Qin N; Zhang Q; Yue W; Zhang S
Thorac Cancer; 2015 Nov; 6(6):678-86. PubMed ID: 26557904
[TBL] [Abstract][Full Text] [Related]
6. Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer.
Cheng Y; Ye Z; Xie Y; Du X; Song S; Ding X; Lin C; Wang B; Li W; Zhang C
Clin Transl Oncol; 2024 Jun; 26(6):1357-1367. PubMed ID: 38145428
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor therapy in pediatric sarcoma: Prognostic implications of pulmonary metastatic cavitation.
Morakote W; Adams LC; Ramasamy SK; Spunt SL; Baratto L; Liang T; Daldrup-Link HE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30629. PubMed ID: 37580891
[TBL] [Abstract][Full Text] [Related]
8. The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer.
Tsui DCC; Holt DE; Patil T; Staley A; Gao D; Kavanagh BD; Schenk EL; Rusthoven CG; Camidge DR
Adv Radiat Oncol; 2024 Jul; 9(7):101516. PubMed ID: 38868503
[TBL] [Abstract][Full Text] [Related]
9. Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?
De Grève J; Decoster L; van Brummelen D; Geers C; Schallier D
Transl Lung Cancer Res; 2012 Jun; 1(2):152-4. PubMed ID: 25806173
[No Abstract] [Full Text] [Related]
10. EGFR, EGFR TKI, and EMSI: a never-ending story.
Kim YC
Transl Lung Cancer Res; 2014 Dec; 3(6):365-7. PubMed ID: 25806321
[No Abstract] [Full Text] [Related]
11. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
[TBL] [Abstract][Full Text] [Related]
12. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
[TBL] [Abstract][Full Text] [Related]
14. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
16. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
17. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
Auliac JB; Fournier C; Audigier Valette C; Perol M; Bizieux A; Vinas F; Decroisette Phan van Ho C; Bota Ouchlif S; Corre R; Le Garff G; Fournel P; Baize N; Lamy R; Vergnenegre A; Arpin D; Marin B; Chouaid C; Gervais R
Target Oncol; 2016 Apr; 11(2):167-74. PubMed ID: 26315967
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
19. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
[TBL] [Abstract][Full Text] [Related]
20. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Tan CS; Gilligan D; Pacey S
Lancet Oncol; 2015 Sep; 16(9):e447-e459. PubMed ID: 26370354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
